Purposes: The purpose of this meta-analysis is to systematically compare the IOP-lowering effect of different microstents combined with phacoemulsification versus phacoemulsification for patients with OAG and cataract.
Methods: This work was done through the data searched from PubMed, EMBASE, and the Cochrane Library. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, this meta-analysis was performed using Revman 5.4 software.
Results: A total of 8 randomized controlled trials (RCTs) were included. Compared with phacoemulsification alone, microstent implantation with phacoemulsification resulted in significant reduction in the postoperative IOP (MD = -1.66, 95%CI: [-2.25 to -1.06]). Patients with medication free and patients with beyond 20% IOP reduction were significantly increased in the microstent implantation with phacoemulsification group compared with phacoemulsification alone group (RR = 1.54, 95%CI: [1.34 to 1.77]; RR = 1.34, 95%CI: [1.24 to 1.45]).
Conclusion: Both microstent implantation with concurrent phacoemulsification and phacoemulsification alone result in a significant reduction in IOP. In terms of both reductions, microstent implantation with phacoemulsification significantly outperforms phacoemulsification alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08820538.2022.2086012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and biocompatibility of a novel Schlemm's canal microstent for glaucoma management.
Sci Rep
October 2024
Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China.
Article Synopsis
- The study evaluated the Wistend microstent, made of Nitinol, for improving fluid drainage in the eye, using New Zealand white rabbits divided into different treatment groups.
- Key tests before and after the procedure, including SS-OCT and SEM, showed that the Wistend significantly reduced intraocular pressure compared to control groups over six months.
- There were no adverse tissue reactions or complications, indicating Wistend's potential as a safe and effective option for managing eye pressure.
Two-Year Retrospective Study of Cataract Surgery and Schlemm Canal Hydrus Microstent in Black and Afro-Latino Patients.
Clin Ophthalmol
October 2024
Advanced Eyecare of New York, New York, NY, USA.
Background: The Hydrus Microstent has been shown to be efficacious in the treatment of Open-angle Glaucoma. We previously reported 1-year results of the Hydrus Microstent in Black and Afro-Latino patients.
Objective: Here we report two-year results of the Hydrus Microstent in Black and Afro-Latino patients with mild to moderate open-angle glaucoma.
Visualization of the Postoperative Position of the Hydrus Microstent Using Automatic 360° Gonioscopy.
J Clin Med
September 2024
Department of Ophthalmology, University of Muenster Medical Center, 48149 Muenster, Germany.
: Glaucoma, one leading cause of irreversible vision loss worldwide, is primarily caused by elevated intraocular pressure (IOP). Recently, minimally invasive glaucoma surgeries (MIGSs) have become popular due to their shorter surgical times, tissue-sparing nature, and faster recovery. One such MIGS, the Hydrus nickel-titanium alloy Microstent, helps lower IOP by improving aqueous humor outflow.
View Article and Find Full Text PDFEarly to late explantation of Hydrus microstent MIGS device: A case series.
Am J Ophthalmol Case Rep
December 2024
Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
Purpose: The Hydrus microstent was approved by the FDA in August 2018 for use with cataract surgery to reduce IOP in patients with mild to moderate primary open angle glaucoma (POAG). Pivotal clinical trials demonstrated its overall safety and efficacy in lowering IOP. However, malpositioning of the implant can result in uveitis-glaucoma-hyphema (UGH) syndrome necessitating device explantation.
View Article and Find Full Text PDFExperimental glaucoma microstent implantation in two animal models and human donor eyes-an micro-computed tomography-based evaluation of applicability.
Quant Imaging Med Surg
August 2024
Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany.
Background: Minimally invasive glaucoma surgery (MIGS) has become an important treatment approach for primary open angle glaucoma. Restoration of aqueous humour drainage by means of alloplastic implants represents a promising treatment option and is itself subject of methodological development. An adequate positioning in the targeted tissue regions is essential is important for the performance of our in-house developed Rostock glaucoma microstent (RGM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!